Why the Same Dose Does Not Mean the Same Protection
Adult RSV vaccination has a population-wide result, but its value is not distributed evenly across every adult. The central question here is why effectiveness was lower in some high-risk groups and how to interpret that finding without concluding that vaccination is futile for the people who may face the most serious consequences. The answer requires separating two ideas that are often compressed into one: a person’s baseline risk of severe RSV, and the relative protection a vaccine provides against that outcome.
Two kinds of risk interact
Baseline risk is the chance that a person will develop severe disease without vaccination, given factors such as age, heart or lung disease, immune status, frailty, and access to rapid escalation of care. Relative vaccine effectiveness asks how much less often the measured outcome occurred among vaccinated people than among comparable unvaccinated people in a study. These are related, but they are not interchangeable.
Imagine two groups that receive the same relative protection. If one group starts with a higher chance of hospitalization, preventing a fraction of that risk can avert more hospital stays in absolute terms. Conversely, a high relative-effectiveness estimate does not tell us how many events a particular person avoids unless we also know the person’s underlying risk. A percentage without a baseline can therefore mislead in both directions: it can make a lower estimate look useless, or make a higher estimate look like a guarantee.
This is the reasoning problem that risk-stratified vaccination is trying to address. A person may have a high baseline risk of severe RSV and a less reliable immune response to vaccination at the same time. That combination does not produce a simple “works” or “does not work” label. It means the decision has to consider the stakes of illness, the protection that has actually been observed in comparable people, and the uncertainty around the estimate.
The two-season IVY Network study made this interaction visible. It estimated effectiveness among adults aged 60 years or older hospitalized with acute respiratory illness. The study was not designed to rank every medical condition, and it did not supply individual predictions. It did, however, show that the average estimate concealed important differences by immune status and cardiovascular disease, while another chronic-disease category looked more similar across groups.
Why immune compromise changes the estimate
The clearest difference involved moderate or severe immunocompromise. Across the two RSV seasons, estimated vaccine effectiveness against hospitalization was 30% among immunocompromised adults, with a 95% confidence interval from −9% to 55%. Among immunocompetent adults, the estimate was 67%, with a confidence interval from 53% to 77%. The difference between the groups was statistically significant in the study.
The negative lower bound deserves careful interpretation. It means the data were imprecise enough that the range compatible with the analysis included little benefit and a value below zero. It does not show that vaccination caused RSV hospitalization or that the vaccine is known to be harmful in immunocompromised adults. Nor does it prove that the true effectiveness is exactly 30%. It signals that the estimate for this subgroup is less certain and could be materially lower than the estimate for immunocompetent adults.
The study’s definition of immunocompromise covered conditions and treatments that can substantially suppress immune function, including active malignancy, solid-organ or hematopoietic-cell transplantation, HIV infection, primary immunodeficiency, and recent use of immunosuppressive medication. These are not minor variations on ordinary health. They can change how the body produces and maintains the immune responses that vaccination is intended to stimulate.
The authors discuss a plausible biological pathway: people with immunocompromising conditions or immunomodulatory treatment may be less likely to mount an adequate immune response after vaccination. The article also cites immunogenicity studies in which solid-organ transplant recipients had lower RSV-neutralizing antibody titers than immunocompetent adults or people with end-stage renal disease. But this mechanism must remain qualified. There is no established serologic correlate of protection for RSV—a validated antibody level that can reliably tell us whether a person is protected—so a lower antibody measurement cannot be converted directly into a precise hospitalization risk.
The clinical pattern among vaccinated RSV cases adds context. Of 821 RSV-positive cases in the study, 63 had been vaccinated. Compared with unvaccinated RSV cases, the vaccinated cases had a higher median comorbidity score and a higher proportion of moderate or severe immunocompromise. Solid-organ transplantation, active solid tumors, and recent immunosuppressive therapy were also more common in the vaccinated case group. Six of the eight vaccinated cases with a solid-organ transplant had received a lung transplant.
These observations do not establish that vaccination failed because of a particular condition, and they are not a comparison of all vaccinated people with all unvaccinated people. They describe the patients who reached the hospital with RSV despite vaccination. The pattern is nevertheless important: breakthrough hospitalization can concentrate among people whose immune systems or underlying illnesses make both severe disease and a weaker vaccine response more plausible. A lower relative-effectiveness estimate in that group should prompt better evidence and careful timing questions, not a conclusion that the dose has no value.
The value question remains tied to baseline risk. Even if a vaccine prevents a smaller proportion of hospitalizations in an immunocompromised population, the population may still have much to gain if its untreated risk of severe RSV is high. The supplied study does not quantify each patient’s absolute risk, so it cannot calculate that individual trade-off. It supports a more modest conclusion: immune status is relevant to expected protection and should not be hidden behind an overall average.
The relationship can be represented without treating any one pathway as deterministic:
The arrows summarize questions the evidence makes relevant, not a complete causal model. A condition can raise the stakes of infection, affect the immune response, or do both. The observed effectiveness estimate is the result of many influences, including study design and unmeasured differences. It should inform judgment rather than replace it.
Heart disease and lung disease do not tell the same story
The cardiovascular finding was also meaningful, but it came from a narrower comparison. Among immunocompetent adults with cardiovascular disease, estimated effectiveness was 56%, with a 95% confidence interval from 32% to 72%. Among immunocompetent adults without cardiovascular disease, it was 80%, with a confidence interval from 62% to 90%. The difference was statistically significant. Of the cardiovascular-disease group, 67% had heart failure.
This result matters for two reasons. First, cardiovascular disease is not merely a background characteristic in an RSV study. RSV can place additional strain on people whose heart and circulation are already vulnerable, and a hospitalization may have more serious consequences. Second, the lower estimate means that people with cardiovascular disease may not receive the same relative protection observed in healthier peers, even when they are not immunocompromised according to the study’s definition.
The article discusses a possible explanation involving the pro-inflammatory state associated with heart disease. Such a state might contribute to susceptibility to RSV and potentially inhibit aspects of the immune response after vaccination. That is a biologically plausible hypothesis, not a mechanism proven by this observational analysis. The study shows an association between cardiovascular disease and a lower effectiveness estimate; it does not isolate inflammation as the cause.
Chronic lung disease produced a different result in the same general analysis. Among immunocompetent adults, estimated effectiveness was 67% for those with chronic lung disease and 68% for those without it. The difference was not statistically significant. This does not mean chronic lung disease is unimportant. Lung disease can raise the chance that an RSV infection becomes severe, and it is included in CDC’s current list of conditions that can increase risk. It means that, in this dataset and comparison, the vaccine-effectiveness estimate did not show a detectable difference between the two chronic-lung groups.
The contrast is a useful warning against treating all chronic conditions as one category. A condition can increase the baseline danger of RSV without producing the same observed change in vaccine effectiveness. Another condition can be associated with a lower effectiveness estimate for reasons that are only partly understood. The study was not large enough to resolve every subtype of heart disease, lung disease, immune suppression, or treatment exposure. The absence of a detected difference for chronic lung disease is therefore not evidence that every person with lung disease has the same protection, just as the cardiovascular result is not a ranking of all cardiac conditions.
Age is a clue, not a complete explanation
A simple age comparison initially appears to show higher effectiveness in the oldest adults. The estimate was 46% for adults aged 60–74 years and 68% for those aged 75 years or older. The difference did not meet conventional statistical significance. More importantly, when the analysis was restricted to immunocompetent adults, the estimates were 67% for ages 60–74 and 68% for ages 75 or older, with no meaningful statistical difference.
Why does that adjustment matter? The two age groups may not contain the same mix of immune compromise and other medical vulnerabilities. If one group has more conditions that reduce immune response, a lower crude estimate could reflect the composition of the group rather than a sharp biological change at a birthday. Restricting the comparison to immunocompetent adults does not remove every age effect, but it tests whether immune status was helping to drive the apparent difference.
This does not prove that age has no biological relevance. Older age can affect immune function, the severity of respiratory disease, and the likelihood of complications. It also remains a practical foundation of current policy: CDC recommends one dose for all adults aged 75 years or older, while adults aged 50–74 are considered through an increased-risk recommendation. The study’s sensitivity analysis simply shows why that policy structure should not be interpreted as proof that vaccine performance switches abruptly at age 75.
The evidence and the policy answer different questions. The study asks how a dose performed among hospitalized adults aged 60 years or older under a particular observational design. CDC guidance sets a recommendation for a broader adult population by considering age, disease risk, clinical judgment, and the totality of available evidence. The study cannot directly estimate effectiveness for adults aged 50–59, and it cannot replace the broader policy process.
What the subgroup findings change
The subgroup findings change the meaning of an average effectiveness number in three ways.
First, they make population averages less sufficient for individual interpretation. An overall estimate can describe the direction and approximate magnitude of protection in the enrolled population while hiding meaningful variation in people with immune compromise or cardiovascular disease. When a recommendation is risk-based, that variation is not a side issue; it is part of the reason the recommendation asks about risk.
Second, they show why lower effectiveness is not the same as low importance. Immunocompromised adults may face both higher consequences from RSV and weaker or less durable responses to a dose. That combination creates a difficult evidence problem, not an obvious reason to abandon prevention. It may justify closer monitoring and better subgroup studies, but the supplied material does not establish a different dose schedule for those patients.
Third, they show why “no difference detected” must be used carefully. The chronic-lung comparison did not find a statistically significant difference, but that result does not guarantee equal protection for every person with lung disease. Similarly, the age-restricted sensitivity analysis reduces one explanation for the crude age pattern without ruling out all biological effects of age.
A responsible clinical conversation therefore starts with questions rather than a new checklist: What is the person’s age? What conditions or treatments raise the chance or consequence of severe RSV? What evidence applies to that condition? How precise is the estimate? Has the person already received a dose? The supplied evidence can support the importance of those questions, but it cannot answer them for a specific patient or rank every possible risk factor.
The larger lesson is that risk stratification is not a promise that medicine can calculate a perfect personal forecast. It is a way to avoid two errors at once: treating everyone as if they face the same disease stakes, and treating one population-average effectiveness estimate as if it describes every immune system. The next question is how time and product differences add another layer of variation—whether protection appears lower after a prior season, what can be said about the two better-studied products, and why the evidence for mResvia remains incomplete.